Modality
Fusion Protein
MOA
AuroraAi
Target
PCSK9
Pathway
Apoptosis
DMDBladder CaSMA
Development Pipeline
Preclinical
~May 2024
→ ~Aug 2025
Phase 1
Nov 2025
→ Feb 2028
Phase 1Current
NCT04335680
338 pts·Bladder Ca
2025-11→2028-02·Not yet recruiting
338 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-211.9y awayInterim· Bladder Ca
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028
P1
Not yet…
Catalysts
Interim
2028-02-21 · 1.9y away
Bladder Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04335680 | Phase 1 | Bladder Ca | Not yet recr... | 338 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 |